

Corinne M Linardic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3955124/publications.pdf>

Version: 2024-02-01

36
papers

1,408
citations

430874

18
h-index

345221

36
g-index

38
all docs

38
docs citations

38
times ranked

2429
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29644.	1.5	18
2	Abstract LB213: Potent antitumor activity of a FGFR4 CART in rhabdomyosarcoma. <i>Cancer Research</i> , 2022, 82, LB213-LB213.	0.9	0
3	Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. <i>European Journal of Cancer</i> , 2022, 172, 367-386.	2.8	19
4	Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28798.	1.5	38
5	Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target. <i>Molecular Oncology</i> , 2021, 15, 2156-2171.	4.6	11
6	Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. <i>Journal of Clinical Medicine</i> , 2021, 10, 1416.	2.4	11
7	Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence. <i>Scientific Reports</i> , 2021, 11, 16505.	3.3	1
8	Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 2859-2871.	1.6	101
9	A method to culture human alveolar rhabdomyosarcoma cell lines as rhabdospheres demonstrates an enrichment in stemness and notch signaling. <i>Biology Open</i> , 2021, 10, .	1.2	2
10	RASSF4 is required for skeletal muscle differentiation. <i>Cell Biology International</i> , 2020, 44, 381-390.	3.0	4
11	Detection of iron deficiency in children with Down syndrome. <i>Genetics in Medicine</i> , 2020, 22, 317-325.	2.4	10
12	Response to Zhang et al.. <i>Genetics in Medicine</i> , 2020, 22, 662-662.	2.4	0
13	Parenting a child with cancer: a couple-based approach. <i>Translational Behavioral Medicine</i> , 2019, 9, 504-513.	2.4	6
14	Insights into pediatric rhabdomyosarcoma research: Challenges and goals. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27869.	1.5	57
15	Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma. <i>International Journal of Cancer</i> , 2019, 144, 2707-2717.	5.1	10
16	Soft Tissue Sarcoma Cancer Stem Cells: An Overview. <i>Frontiers in Oncology</i> , 2018, 8, 475.	2.8	37
17	Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis. <i>Cancer Research</i> , 2018, 78, 5513-5520.	0.9	12
18	The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. <i>Cell Reports</i> , 2017, 19, 2304-2318.	6.4	53

#	ARTICLE	IF	CITATIONS
19	A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma. <i>Molecular Cancer Research</i> , 2017, 15, 1777-1791.	3.4	49
20	Recent Insights into Notch Signaling in Embryonal Rhabdomyosarcoma. <i>Current Drug Targets</i> , 2016, 17, 1235-1244.	2.1	6
21	A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas. <i>Frontiers in Oncology</i> , 2015, 5, 190.	2.8	60
22	Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma. <i>PLoS ONE</i> , 2015, 10, e0140781.	2.5	39
23	Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma. <i>Clinical Cancer Research</i> , 2015, 21, 4868-4880.	7.0	18
24	Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2143-2153.	4.1	53
25	Asparaginase-Induced Hypertriglyceridemia Presenting as Pseudohyponatremia during Leukemia Treatment. <i>Case Reports in Pediatrics</i> , 2014, 2014, 1-5.	0.4	4
26	Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. <i>Journal of Clinical Investigation</i> , 2014, 124, 285-296.	8.2	94
27	RAS and ROS in Rhabdomyosarcoma. <i>Cancer Cell</i> , 2013, 24, 689-691.	16.8	18
28	FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma. <i>Clinical Cancer Research</i> , 2012, 18, 3780-3790.	7.0	76
29	In Vivo Imaging of Tumor-Propagating Cells, Regional Tumor Heterogeneity, and Dynamic Cell Movements in Embryonal Rhabdomyosarcoma. <i>Cancer Cell</i> , 2012, 21, 680-693.	16.8	110
30	Inhibition of the Notch-Hey1 Axis Blocks Embryonal Rhabdomyosarcoma Tumorigenesis. <i>Clinical Cancer Research</i> , 2011, 17, 7324-7336.	7.0	51
31	PAX3-FOXO1 fusion gene in rhabdomyosarcoma. <i>Cancer Letters</i> , 2008, 270, 10-18.	7.2	121
32	Defining the Cooperative Genetic Changes That Temporally Drive Alveolar Rhabdomyosarcoma. <i>Cancer Research</i> , 2008, 68, 9583-9588.	0.9	71
33	The PAX3-FKHR Fusion Gene of Rhabdomyosarcoma Cooperates with Loss of p16INK4A to Promote Bypass of Cellular Senescence. <i>Cancer Research</i> , 2007, 67, 6691-6699.	0.9	57
34	Genetic Modeling of Human Rhabdomyosarcoma. <i>Cancer Research</i> , 2005, 65, 4490-4495.	0.9	79
35	Myelodysplasia as masquerader: A woman with hypereosinophilic syndrome and twelve years of chronic ITP?. <i>Medical and Pediatric Oncology</i> , 2002, 39, 137-138.	1.0	2
36	Modulation of cell growth and differentiation by ceramide. <i>FEBS Letters</i> , 1992, 307, 211-214.	2.8	92